Nutritional Supplement Toxicity Clinical Trial
— KnoVIBOfficial title:
Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People
Verified date | April 2019 |
Source | Saarland University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The standard recommendation to prevent osteoporosis is to supplement low doses of vitamin D and calcium. Hyperhomocysteinemia has been related to increased risk of osteoporosis.
Status | Completed |
Enrollment | 93 |
Est. completion date | July 2011 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - age> 50 years, - male and female Exclusion Criteria: - renal dysfunction, - recent stroke or coronary event within the last 3 months, - current cancer, - antifolate treatment, - ileum resection, - existing B vitamins supplementation, - megaloblastic anemia, - osteoporotic patients treated with pharmacological doses of vitamin D or antiosteoporotic drugs. Termination criteria were: - indication for a high-dose vitamin B supplementation, - coronary or vascular event, - or surgical procedures during the study. |
Country | Name | City | State |
---|---|---|---|
Germany | University of Saarland | Homburg | Saarland |
Lead Sponsor | Collaborator |
---|---|
Saarland University |
Germany,
Herrmann W, Kirsch SH, Kruse V, Eckert R, Gräber S, Geisel J, Obeid R. One year B and D vitamins supplementation improves metabolic bone markers. Clin Chem Lab Med. 2013 Mar 1;51(3):639-47. doi: 10.1515/cclm-2012-0599. — View Citation
Hübner U, Geisel J, Kirsch SH, Kruse V, Bodis M, Klein C, Herrmann W, Obeid R. Effect of 1 year B and D vitamin supplementation on LINE-1 repetitive element methylation in older subjects. Clin Chem Lab Med. 2013 Mar 1;51(3):649-55. doi: 10.1515/cclm-2012- — View Citation
Kirsch SH, Herrmann W, Kruse V, Eckert R, Gräber S, Geisel J, Obeid R. One year B-vitamins increases serum and whole blood folate forms and lowers plasma homocysteine in older Germans. Clin Chem Lab Med. 2015 Feb;53(3):445-52. doi: 10.1515/cclm-2014-0540. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in bone formation markers | Concentrations of bone formation markers in plasma [OC (ng/ml), BAP (U/L)]: are measured: if all are increased indicate enhanced bone formation | baseline, 6 and 12 months | |
Secondary | Changes in plasma choline and betaine | plasma choline and betaine (all µmol/L): if both increased indicate saving betaine and choline | baseline and aftter 12 months | |
Secondary | Changes in global DNA methylation | global DNA methylation [line 1-methylation (expressed as %)] | baseline and after 12 months | |
Secondary | Changes in gene-specific gene methylation | After isolating DNA from whole blood, changes in methylation of targeted genes is studied (expressed as %) | baseline and after 12 months | |
Secondary | Changes in TMAO | Plasma concentrations of TMAO ((µmol/L) is measured | baseline and after 6 and 12 months | |
Secondary | Changes in phospholipid concentration in plasma | Plasma phospholipids ((µmol/L) are measured | baseline and after 12 months | |
Secondary | Changes in concentrations of bone resorption markers | concentrations of bone resorption markers [plasma TRAP5b (U/L), urine DPD (nmol//mmol creatinine)]: if both are increased indicate enhanced bone resorption | baseline, 6 and 12 months | |
Secondary | Changes in plasma homocysteine concentrations | changes in plasma homocysteine (µmol/L) between the time points | baseline, 6 and 12 months | |
Secondary | Changes in plasma levels of folate | changes in serum and whole blood folate (nmol/L) | baseline, 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04051840 -
Safely and Efficacy of ClinOleic-based Lipid Parenteral Nutrition
|
Phase 1 | |
Completed |
NCT03588897 -
The Impact of Oral Nutritional Supplements on the Nutritional Status of Elderly Patients
|
Phase 3 |